TREATMENT OF PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE FONTAINE STAGE-III AND STAGE-IV WITH INTRAVENOUS ILOPROST - AN OPEN STUDY IN 900 PATIENTS

In an open study the clinical efficacy and tolerability of the stable prostacyclin (PGI(2)) analogue iloprost in the treatment of 900 patien ts with advanced peripheral arterial occlusive disease (Fontaine stage III and IV), enrolled by 169 centres, were investigated. Of these pat ients, treated with infusions over 6 h daily up to 42 days, 853 could be evaluated: four were excluded because of wrong diagnosis. The respo nder rates, defined as pain relief, no or reduced use of analgesics (s tage III and IV), improvement of trophic lesions, i.e. complete or gre ater than or equal to 50% healing of ulcers, demarcation of necroses ( stage IV), and global improvement, were 75.0% and 66.0% in stage III a nd 46.3% and 41.8% in stage IV patients in the valid case and intentio n-to-treat group, respectively. A complete healing of ulcers was obser ved in 12.3% of those patients (n=375) presenting with ulcerations at the beginning of treatment. Diabetic and non-diabetic patients were co mparable with regard to efficacy of iloprost. 71.4% and 66.2% (stage I II and IV) of initial responders at 6 months follow-up were still free from rest pain and showing complete or partial healing of trophic les ions. 7.9% of stage III and 16.9% of stage IV patients underwent major amputation during the whole study period with a reduced amputation ra te in responders compared to non-responders in stage IV 7.9% stage III and 13.2% stage IV patients died. 83.2% and 86.0% of stage III and IV patients presented with adverse events at any time of treatment, main ly headache, nausea and flush as well as gastrointestinal symptoms, oc curring mostly during the titration phase. The investigators' judgemen t, however, revealed a very good and good tolerability in 74.8% of sta ge III and in 73.7% of stage IV patients.